ABSTRACT
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly used antidepressant medications today. 1 Because they inhibit platelet aggregation, these agents increase the risk of gastrointestinal bleeding; however, studies conflict on their association with brain hemorrhage. 2 We performed a systematic review and meta-analysis of observational studies reporting on the association of SSRIs with brain hemorrhage. Because definitions for this outcome vary considerably between studies, we pooled studies according to the subtype of hemorrhage reported.
METHODS
We screened Medline, Web of Science (including conference proceedings), EMBASE, Scopus, ProQuest Dissertations, and article reference lists for controlled epidemiologic studies reporting risk estimates for the association of SSRIs with brain hemorrhage. Studies had to include a control group not receiving SSRI therapy; prospective cohorts, retrospective cohorts, casecrossover studies, and case-control designs were permitted. We focused on observational studies because clinical trials of antidepressant medications rarely report intracranial hemorrhagic events. Hemorrhage was categorized according to the definitions used in the original studies: 1) any intracranial hemorrhage; 2) hemorrhagic stroke (a composite of intracerebral and subarachnoid hemorrhage); 3) intracerebral hemorrhage alone; and 4) subarachnoid hemorrhage alone.
We extracted both unadjusted and multivariate-adjusted risk estimates which we then synthesized using DerSimonian-Laird fixed effect rate ratios (RRs) with 95% confidence interval (CI). 3 In a sensitivity analysis, we repeated our analyses using random effects models. Studies contributing only unadjusted results were analyzed only in unadjusted models. We quantified heterogeneity using the I 2 statistic. 4 We used Duval-and-Tweedie trim-and-fill analysis to quantify whether publication bias influenced the results. We also analyzed the additive risk of hemorrhage (of any type) in relation to SSRI exposure and oral anticoagulants vs oral anticoagulants alone. Finally, we used subgroup analysis to determine whether study design had an influence on the results.
RESULTS
Our search retrieved 2,493 citations for screening by titles, abstracts, and key words. Of these, 81 citations were potentially relevant and reviewed as full text (including 11 doctoral theses). Sixteen articles were eligible for the review, comprising 506,411 subjects ( Abbreviations: ACE ϭ angiotensin-converting enzyme; ASA ϭ acetylsalicylic acid; COPD ϭ chronic obstructive pulmonary disease; MI ϭ myocardial infarction; NSAID ϭ nonsteroidal anti-inflammatory drug; PPI ϭ proton pump inhibitor; SSRI ϭ selective serotonin reuptake inhibitor; TCA ϭ tricyclic antidepressant.
Intracranial hemorrhage was related to SSRI exposure in both unadjusted (RR 1.48, 95% CI 1. Heterogeneity was low for most analyses with the exception of unadjusted intracerebral hemorrhage (I 2 ϭ 71%, p ϭ 0.01); however, random effects models gave materially similar results (table 2) . In a subset of 5 studies reporting oral anticoagulant exposure (3 studies of intracranial hemorrhage and 1 each reporting hemorrhagic stroke and intracerebral hemorrhage), SSRI exposure in combination with oral anticoagulants was associated with an increased risk of bleeding compared with oral anticoagulants alone (RR 1.56, 95% CI 1.33-1.83). When all studies were analyzed together, increased risk was seen across cohort studies (1.61, 95% CI 1.04 -2.51), casecontrol studies (odds ratio [OR] 1.34, 95% CI 1.20 -1.49), and case-crossover studies (OR 4.24, 95% CI 1.95-9.24). Finally, Duval-and-Tweedie trim-and-fill analyses yielded concordant results, suggesting that publication bias was not operative.
Seven studies performed analyses by duration of exposure (table 3) . e1,e3,e5,6,e11,e14,e16 Six of the 7 suggested that short-term, recent exposure was more strongly associated with hemorrhagic events than long-term exposure, a finding in keeping with the reported diminution of platelet function following several weeks of exposure to SSRIs. 5 Platelet function may improve with prolonged exposure, or short-term 
